Praxis Precision Medicines, Inc.

PRAX · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.3%

Institutions123.2%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$0	$8.55M	$2.45M	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$326.20M	-$200.16M	-$126.37M	-$214.99M	-$167.33M	-$61.97M
Operating income as a percentage of revenue.	–	-2340.3%	-5164.4%	–	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$303.30M	-$182.80M	-$123.30M	-$214.00M	-$167.06M	-$61.82M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-13.00	$-10.00	$-18.00	$-4.00	$-3.94	$-7.86
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-13.00	$-10.00	$-18.00	$-4.00	$-3.94	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$357.33M	$215.37M	$81.30M	$61.62M	$138.70M	$296.61M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$937.91M	$483.11M	$87.95M	$115.13M	$292.75M	–
Everything the company owes — debt, unpaid bills, and other obligations.	$59.77M	$37.66M	$18.28M	$39.02M	$41.94M	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$878.14M	$445.45M	$69.67M	$76.11M	$250.81M	–

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$249.07M	-$131.76M	-$111.14M	-$185.04M	-$124.55M	-$52.62M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$56000	$0	$50000	$444000	$1.05M	–
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$249.12M	-$131.76M	-$111.19M	-$185.49M	-$125.60M	–

	You	Peer avg
P/E	–	44.8
Revenue Growth	–	+151.1%
ROE	-38.9%	-19.7%

Praxis Precision Medicines, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison